Changeflow GovPing Pharma & Drug Safety Long-Acting Injectable Formulations Comprising ...
Routine Rule Added Final

Long-Acting Injectable Formulations Comprising an Isoxazoline Active Agent (EP3261617A1)

Favicon for changeflow.com EPO Patent Bulletin - Pharma (A61K)
Published
Detected
Email

Summary

The European Patent Office published European patent application EP3261617A1 for Boehringer Ingelheim Vetmedica GmbH covering long-acting injectable formulations comprising isoxazoline active agents. The application classifies under IPC codes A61K 31/422, A61K 31/42, A61K 9/00, and A01N 43/80. The application designates 36 European contracting states including Germany, France, United Kingdom, Italy, Spain, and other EU member states.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The EPO published European patent application EP3261617A1 filed by Boehringer Ingelheim Vetmedica GmbH for long-acting injectable formulations containing isoxazoline active agents, with filing date April 8, 2026. The application covers methods of preparing and using these formulations, classified under multiple IPC codes related to pharmaceutical compositions (A61K) and parasiticidal agents (A01N, A61P).

For pharmaceutical manufacturers and animal health companies, this published application establishes a priority date for isoxazoline injectable formulation claims. Competitors developing similar long-acting parasiticidal injectables should conduct freedom-to-operate analyses and monitor the prosecution of this application through the EPO examination process.

What to do next

  1. Monitor patent register for examination status
  2. Review application claims for freedom-to-operate analysis
  3. Assess IP portfolio implications for animal health products

Archived snapshot

Apr 16, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

LONG-ACTING INJECTABLE FORMULATIONS COMPRISING AN ISOXAZOLINE ACTIVE AGENT, METHODS AND USES THEREOF

Publication EP3261617A1 Kind: A1 Apr 08, 2026

Applicants

Boehringer Ingelheim Vetmedica GmbH

Inventors

CADY, Susan, Mancini, CHEIFETZ, Peter, GALESKA, Izabela, DE FALLOIS, Loic Le Hir

IPC Classifications

A61K 31/422 20060101AFI20251030BHEP A61P 43/00 20060101ALI20251030BHEP A61P 33/14 20060101ALI20251030BHEP A61P 33/00 20060101ALI20251030BHEP A61K 47/10 20170101ALI20251030BHEP A61K 31/42 20060101ALI20251030BHEP A61K 31/69 20060101ALI20251030BHEP A01N 43/80 20060101ALI20251030BHEP A61P 33/10 20060101ALI20251030BHEP A61K 9/00 20060101ALI20251030BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 8th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3261617A1

Who this affects

Applies to
Pharmaceutical companies Manufacturers Investors
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent examination IP licensing Drug formulation
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals

Get alerts for this source

We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!